stockrowIceCure Medical Ltd.
ICCMIceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- −2,068.2%
- Free cash flow
- +3.88%
- Total debt
- −64.4%
Quarter to June 2026, against a year earlier
Follow ICCM
Alert me
IceCure Medical Ltd. (ICCM) EV/Sales
As of 6 November 2026, IceCure Medical Ltd. (ICCM) trades at a EV/Sales of −3.8×. Over the past ten years it has ranged from −3.8× (November 2026) to 1,393× (September 2021) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.7× | (40.51%) |
| FY2024 | 16.4× | (96.38%) |
| FY2023 | 452× | 47.29% |
| FY2022 | 307× | (55.57%) |
| FY2021 | 691× | 2,688.89% |
| FY2020 | 24.8× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 5.2× | (77.10%) |
| Mar 2025 | 22.9× | 23.84% |
| Mar 2024 | 18.5× | (94.48%) |
| Sep 2023 | 335× | (2.43%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. | −3.8× |
| CODX Co-Diagnostics, Inc. compare | −3.5× |
| AIDX 20/20 Biolabs Inc. compare | −0.7× |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| AMIX Autonomix Medical, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| IVF INVO Fertility, Inc compare | 0.2× |
| ADGM Adagio Medical Holdings, Inc. compare | 30.6× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)